# EU Secondary Data Post-Authorisation Safety Study of AZD1222

> **NCT05126992** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 5321930 (actual)

## Conditions studied

- COVID-19, Vaccine Adverse Events of Special Interest

## Interventions

- **BIOLOGICAL:** AZD1222

## Key facts

- **NCT ID:** NCT05126992
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-18
- **Primary completion:** 2024-01-24
- **Final completion:** 2024-01-24
- **Target enrollment:** 5321930 (ACTUAL)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05126992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05126992, "EU Secondary Data Post-Authorisation Safety Study of AZD1222". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05126992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*